Evidence map›Paper›PMID 40662767›Full record

ArticleOncoimmunology2025

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates.

Oliver Kepp, Guido Kroemer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Oliver KeppUniversité Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Equipe labellisée parla Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0002-6081-9558
Guido KroemerUniversité Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Equipe labellisée parla Ligue contre le cancer, Institut Universitaire de France, Paris, France.ORCID 0000-0002-9334-4405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving ADC design and therapeutic synergy through informed combination with immunotherapies.

Indexed as

Bystander EffectImmunoconjugatesImmunogenic Cell DeathNeoplasmsAnimalsHumansImmunotherapyImmunoconjugatesCancerCD47cell stressimmunotherapy

Identifiers

PMID40662767
PMCPMC12269677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.